GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR) Meeting II

DRESDEN, Germany, May 15, 2020 /PRNewswire/ — GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced acceptance of three presentations on pre-clinical data for its proprietary universal CAR-T platform…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.